Literature DB >> 14760953

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.

E L J Hoogervorst1, N F Kalkers, G R Cutter, B M J Uitdehaag, C H Polman.   

Abstract

OBJECTIVE: To prospectively characterize the relation between two-year changes in functional impairment as measured by the Multiple Sclerosis Functional Composite (MSFC) and changes in patient perceived disability as measured by the Guy's Neurological Disability Scale (GNDS).
METHODS: One hundred and eighty-eight patients with multiple sclerosis (MS) were recruited at our outpatient clinic. Impairment and disability were assessed using the MSFC and GNDS at baseline and follow-up. Longitudinal correlations were studied between changes in MSFC and GNDS and their corresponding components. We also studied changes in GNDS in relation to what can be classified as a reliable change in MSFC; for example, 20% change in each MSFC component or a change of 0.5 in total MSFC score. In addition, we studied the change in total number of GNDS subcategories with a score of 3 or higher in relation to the predefined MSFC changes, these subcategories being indicative of the requirement for help by another person.
RESULTS: Despite good cross-sectional correlations between MSFC and GNDS, no significant correlation was found between longitudinal changes in MSFC and GNDS. Analysing the change in GNDS in relation to the predefined MSFC changes shows that GNDS changes are nicely rank ordered when more stringent definitions of reliable change were applied. In addition, analysing the number of GNDS subcategories scored 3 or higher indicate that there is a profile of worsening on the MSFC being associated with increase in the amount of help required from others.
CONCLUSION: Our longitudinal data suggest that a reliable change is associated with a likewise change in patient perceived disability, the smallest reliable change being identified by at least 20% change in each MSFC component.

Entities:  

Mesh:

Year:  2004        PMID: 14760953     DOI: 10.1191/1352458504ms972oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

1.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

2.  A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

Authors:  J Furby; T Hayton; D Altmann; R Brenner; J Chataway; K J Smith; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2010-05-01       Impact factor: 4.849

Review 3.  Performance and Capacity Measurement of the Lower Extremities in Multiple Sclerosis -How to Approach?

Authors:  Sıla Usar İncirli; Özlem Taşkapilioğlu
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

4.  Treatment of walking impairment in multiple sclerosis with dalfampridine.

Authors:  Andrew R Blight
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

5.  The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).

Authors:  Lisa Costelloe; Killian O'Rourke; Hugh Kearney; Christopher McGuigan; Lisa Gribbin; Marguerite Duggan; Leslie Daly; Niall Tubridy; Michael Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-01       Impact factor: 10.154

6.  Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.

Authors:  Marcus W Koch; Jop P Mostert; Jerry S Wolinsky; Fred D Lublin; Bernard Uitdehaag; Gary R Cutter
Journal:  Neurology       Date:  2021-08-25       Impact factor: 11.800

Review 7.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

8.  The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.

Authors:  Peter Feys; Ilse Lamers; Gordon Francis; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

9.  Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.

Authors:  Diego Cadavid; Stephanie Jurgensen; Sophia Lee
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

Review 10.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.